FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. A method is described for constructing a library of polynucleotides of interest in a poxvirus-based vector system, such as the smallpox vaccine virus, where the polynucleotides of interest encode the polypeptides of interest. The method involves constructing a library in the presence of a poxvirus assembly inhibitor, such as rifampicin, which allows the construction of libraries with greater complexity and diversity than in previous methods.
EFFECT: invention expands the arsenal of methods for constructing libraries of polynucleotides.
32 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DISPLAY OF AN INTEGRAL MEMBRANE PROTEIN ON EXTRACELLULAR ENVELOPED POXVIRUS VIRIONS | 2017 |
|
RU2759846C2 |
| VIRAL VACCINES | 2017 |
|
RU2778312C2 |
| VIRAL VECTOR MANUFACTURE | 2014 |
|
RU2658487C2 |
| LIBRARY OF CONCENTRATION-DEPENDENT ION BINDING MOLECULES | 2012 |
|
RU2812861C1 |
| COMBINATION OF POXVIRUS ENCODING HUMAN PAPILLOMA VIRUS POLYPEPTIDES, AND IL-2 WITH ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824962C1 |
| CANCER THERAPY BY COMBINED USE OF ONCOLYTIC SMALLPOX VACCINE VIRUS AND IMMUNE CONTROL POINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINED DRUG FOR USE IN CANCER THERAPY | 2019 |
|
RU2788874C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| COMPOSITIONS OF RECOMBINANT CDV AND ITS USE | 2011 |
|
RU2567337C2 |
| COMBINATION THERAPY FOR TREATING CANCER WITH POXVIRUS EXPRESSING TUMOUR ANTIGEN AND ANTAGONIST AND/OR AGONIST OF IMMUNE CHECKPOINT INHIBITOR | 2014 |
|
RU2714142C2 |
| PERSONALIZED VACCINE | 2018 |
|
RU2779987C2 |
